Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT neg PDGFRB over exp |
| Therapy | Imatinib |
| Indication/Tumor Type | breast cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT neg PDGFRB over exp | breast cancer | no benefit | Imatinib | Phase II | Actionable | In a Phase II trial, Gleevec (imatinib mesylate) treatment demonstrated no clinical activity, resulted in no objective response (0/13) in patients with metastatic breast cancer demonstrating Pdgfrb overexpression and negative Kit expression (PMID: 18515258). | 18515258 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (18515258) | Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. | Full reference... |